Indevus files patent application for pagoclone as treatment for premature ejaculation

By Lisa Kerner

Erie, Pa., March 7 - Indevus Pharmaceuticals, Inc. said it has filed a patent application with the U.S. Patent Office covering the use of pagoclone as a treatment for premature ejaculation (PE), which affects about 30% of the adult male population.

Pagoclone, a selective, non-sedating GABA-A receptor partial agonist, is being studied by Indevus in a phase 2 trial for the treatment of stuttering. It is also shown to reduce the symptoms of panic disorder and generalized anxiety disorder in clinical studies.

"We have found evidence within our existing database that patients have described ejaculatory delay on pagoclone," chairman, president and chief executive officer Glenn L. Cooper said in a company news release.

"Based on these observations and the pharmacologic rationale, we intend to form an internal project team to explore the clinical and regulatory path to proof of concept studies of pagoclone as an on-demand oral therapy for men with PE."

There are no approved oral drugs in the United States for the treatment of PE, officials said.

In early 2005, Indevus was granted a new U.S. patent covering the use of pagoclone for the treatment of stuttering.

Indevus is a Lexington, Mass.-based biopharmaceutical company engaged in the acquisition, development and commercialization of products targeting urology, gynecology and men's health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.